Verapamil [clinicaltrials_resource:2753778eef95fee9b65cdf04a13501ee]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00331643 [clinicaltrials_resource:04e94b8a43da0e6fb95715b99650bb9c]eligibility for clinicaltrials:NCT00087386 [clinicaltrials_resource:1dcdf36881b638564b2dbe9dd1a090ed]eligibility for clinicaltrials:NCT00107536 [clinicaltrials_resource:273f28a85c6566d76ff76854cd53b9fb]eligibility for clinicaltrials:NCT00118157 [clinicaltrials_resource:38c27da684633d4e18d079b4d14c3854]eligibility for clinicaltrials:NCT00397787 [clinicaltrials_resource:44f7445b33573724f39d2c3350c2edd2]eligibility for clinicaltrials:NCT00378911 [clinicaltrials_resource:90e2573b962fa7b00d8bc3d81c673d4b]eligibility for clinicaltrials:NCT00096499 [clinicaltrials_resource:a07408bbc65c5b2266e419ce0526be68]eligibility for clinicaltrials:NCT00906360 [clinicaltrials_resource:ab102d1f180ab3114d9eef4e4cd8cffd]eligibility for clinicaltrials:NCT00387920 [clinicaltrials_resource:ae648621e7eda92397728786d3a31e65]eligibility for clinicaltrials:NCT00398112 [clinicaltrials_resource:baa879f991df91a619bf63a4eb76ddf8]eligibility for clinicaltrials:NCT00070525 [clinicaltrials_resource:bbc57e24ec459e18f6e64dc2c331a766]eligibility for clinicaltrials:NCT01143857 [clinicaltrials_resource:d199266ab351b2a512c3cb27f8141c45]eligibility for clinicaltrials:NCT00119236 [clinicaltrials_resource:d8177edb3af609f1c135ac1b3cd473fc]eligibility for clinicaltrials:NCT00058253 [clinicaltrials_resource:efa3f75555d306a863b90f3f66cc9ff9]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels [clinicaltrials:NCT00104247]Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria [clinicaltrials:NCT00104260]INVEST: INternational VErapamil SR Trandolapril STudy [clinicaltrials:NCT00133692]A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels [clinicaltrials:NCT00225615]Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) [clinicaltrials:NCT00234858]Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) [clinicaltrials:NCT00234871]Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension [clinicaltrials:NCT00235001]A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) [clinicaltrials:NCT00235014]Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet [clinicaltrials:NCT00272792]RATe Control in Atrial Fibrillation [clinicaltrials:NCT00313157]A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension [clinicaltrials:NCT00325962]clinicaltrials:NCT00332189Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy [clinicaltrials:NCT00348530]Therapy With Verapamil or Carvedilol in Chronic Heart Failure [clinicaltrials:NCT00374465]A Phase 2 Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease [clinicaltrials:NCT00403494]clinicaltrials:NCT00435331A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease [clinicaltrials:NCT00445978]Sapropterin Expanded Access Program [clinicaltrials:NCT00484991]Pharmacotherapy of Treatment-Resistant Mania [clinicaltrials:NCT00518947]A Phase 2, Pharmacokinetic Study of the Effects of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction [clinicaltrials:NCT00532844]Verapamil and Catamenial Epilepsy [clinicaltrials:NCT00559169]Drug Discrimination in Methadone-Maintained Humans Study 1 [clinicaltrials:NCT00593463]Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [clinicaltrials:NCT00647673]Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg [clinicaltrials:NCT00648050]Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [clinicaltrials:NCT00648401]Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [clinicaltrials:NCT00649805]Bioequivalence Study Of Verapamil [clinicaltrials:NCT00668967]Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives [clinicaltrials:NCT00679653]clinicaltrials:NCT00688844Combination of Hydroxyurea and Verapamil for Refractory Meningiomas [clinicaltrials:NCT00706810]An Interaction Study of Ketoconazole/Verapamil Versus AZD1305 [clinicaltrials:NCT00707551]Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction [clinicaltrials:NCT00712894]Sapropterin in Individuals With Phenylketonuria [clinicaltrials:NCT00730080]A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects [clinicaltrials:NCT00789568]Cluster Headache Cortivazol Injection (CHCI) [clinicaltrials:NCT00804895]clinicaltrials:NCT00838435clinicaltrials:NCT00850070clinicaltrials:NCT00983242clinicaltrials:NCT01082328clinicaltrials:NCT01114737
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Verapamil [clinicaltrials_resource:2753778eef95fee9b65cdf04a13501ee]
Bio2RDF identifier
2753778eef95fee9b65cdf04a13501ee
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2753778eef95fee9b65cdf04a13501ee
identifier
clinicaltrials_resource:2753778eef95fee9b65cdf04a13501ee
title
Verapamil
@en
type
label
Verapamil [clinicaltrials_resource:2753778eef95fee9b65cdf04a13501ee]
@en